Karl Deisseroth Won a Nobel Prize at 12:27 a.m. Then He Made His Kids' School Lunches
Written: October 6, 2026. Why he is trending: Karl Deisseroth was named a winner of the 2026 Nobel Prize in Physiology or Medicine on October 5, 2026, for work that led to optogenetics.
At 12:27 a.m. Pacific time on Monday, a phone rang in a faculty home in Stanford, California. Karl Deisseroth missed the call. He had spent the evening reviewing papers and emailing students in his lab, and he had just lain down. Seconds later, the phone belonging to his wife, Michelle Monje-Deisseroth, rang instead. The voice on the other end asked one short question: "May we speak with Karl?"
It was the Nobel Assembly in Stockholm. Deisseroth, born in 1971, had just won the 2026 Nobel Prize in Physiology or Medicine.
"I almost felt as if I'd lost the power of forming words," he told the Associated Press. "But I recovered after a minute or two."
An hour after the announcement, with cameras in his living room and reporters on Zoom, he described his state simply: "No real sleep was achieved."
Then, at 6:30 a.m., with phone calls still coming in, he asked the Stanford communications team for a break. His children were waking up, and they would need lunch before school. He went to the kitchen and made six sandwiches: four for his son Hudson, with ranch dressing, cheddar, salami and turkey, and two more for his daughters Sophie and Emma. Emma's almond butter, honey and cinnamon had to be on raisin bread. That part, apparently, was non-negotiable.
That morning captures something worth pausing on. The person who just received the highest honour in medicine is also a father of five who makes school lunches, works past midnight, and drinks his coffee from a mug that reads, "That's what I do. I drink and I know things."
When a Stanford representative asked whether the neighbours might mind the late-night commotion, Monje-Deisseroth shrugged it off. They live in faculty housing, she said, and "there are a lot of Nobels in the neighbourhood." She later told Stanford Medicine that she was not surprised by the award at all: "I'm just so delighted. I know I'm biased, but he's really transformed the field of neuroscience, and actually several other fields."
Why Karl Deisseroth Is Trending in the US Right Now
Deisseroth is trending in the United States because of one line read out in Stockholm on Monday: he shares the 2026 Nobel Prize in Physiology or Medicine with Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg, "for their discoveries concerning light-gated ion channels and optogenetics."
| Detail | Who and What |
|---|---|
| Prize | 2026 Nobel Prize in Physiology or Medicine, announced October 5, 2026 by the Nobel Assembly at Karolinska Institutet, Stockholm |
| Laureates | Karl Deisseroth (Stanford University and Howard Hughes Medical Institute, USA), Peter Hegemann (Humboldt University of Berlin, Germany), Georg Nagel (University of Würzburg, Germany) |
| Citation | For their discoveries concerning light-gated ion channels and optogenetics |
| Award value | 12 million Swedish kronor, roughly 1.2 million US dollars, divided equally among the three |
| Deisseroth's roles | D. H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences, and a practicing board-certified psychiatrist |
| Stanford record | Reported as Stanford's 37th Nobel laureate and its fourth in physiology or medicine |
But the trending part was never only the science. It was the image of a man who, minutes after the most important phone call of his life, quietly went back to being a dad.
The Man Behind the Microscope
Deisseroth's path runs through two worlds that rarely sit in the same person. He finished his undergraduate degree in biochemical sciences at Harvard summa cum laude, then earned both a PhD in neuroscience, in 1998, and an MD, in 2000, at Stanford. He completed his medical internship and adult psychiatry residency there and is board-certified in psychiatry.
Then he did something unusual for a laboratory scientist. He kept seeing patients.
He still treats people living with treatment-resistant depression and autism spectrum disorders, using medication and neural stimulation alongside everything he learns at the bench. Clinical psychiatry is not a side note in his career. Colleagues and reviewers have described his book, Projections: A Story of Human Emotions, published in 2021, as built around the stories of his patients rather than around his instruments.
He is also, by the account of his own dean, a reader. Jennifer Widom, dean of the Stanford School of Engineering, called him a "renaissance man" with a love of literature and poetry. That is not decoration. Deisseroth has argued that literature can offer a window into another mind that is sometimes more useful than any microscope lens, which is a strange thing for an engineer of brain circuits to believe.
His wife is not a bystander in this world either. Michelle Monje-Deisseroth is a pediatric neuro-oncologist and a Howard Hughes Medical Institute investigator at Stanford. When the Nobel call came, the household already understood what it meant.
The Science, Explained Without Jargon
Here is the strange and beautiful part of this story. It starts with an alga that swims toward light.
In the early 1990s, Peter Hegemann was studying Chlamydomonas, a single-celled green alga, and wondering how it managed to move toward a light source. Working with Georg Nagel, he found the answer: a protein in the cell membrane called channelrhodopsin. When blue light hits it, a channel opens, charged ions flow through, and the cell produces an electrical signal. Crucially, they showed it worked when placed in other cell types too.
At that point it was a curiosity in plant and algal biology. Deisseroth heard about it. He wrote to Nagel and asked for the DNA.
What happened next is the reason two thirds of this prize exists at all. Deisseroth's team introduced the gene into rat nerve cells grown in a dish. He worried the delicate neurons might react badly to a foreign protein. They did not. When the team switched on blue light, the cells fired. A nerve signal was generated, and it could travel to neighbouring cells.
Then he went further. His lab delivered the gene into the brains of living mice and inserted an ultrathin, flexible optical fibre so light could reach deep brain tissue. By shining light, they could make a mouse's whiskers move. In another experiment, they switched on a set of neurons suspected of controlling wakefulness, and sleeping mice woke up. His team also engineered an opsin triggered by yellow light that silences neurons instead of activating them, which meant the tool could now do both: on and off.
| Year | What Happened | Why It Mattered |
|---|---|---|
| Early 1990s | Hegemann begins investigating how Chlamydomonas alga responds to light | Starts the trail that leads to channelrhodopsin |
| 2002 to 2004 | Gero Miesenböck achieves the first genetic light-sensitisation of non-photoreceptive neurons; Zhuo-Hua Pan tests channelrhodopsin in retinal ganglion cells | Other researchers were circling the same idea from different angles |
| 2005 | Deisseroth's lab publishes work showing channelrhodopsin-2 makes mammalian nerve cells fire with blue light; Ed Boyden is first author | The technique enters neuroscience as a usable tool |
| 2005 to 2007 | Optical fibre delivery into living mice; behaviour controlled with light; an inhibitory yellow-light opsin is developed | Turns a dish experiment into control of a living, behaving brain |
| Later years | CLARITY renders brain tissue transparent; ensemble optogenetics records and replays firing patterns; human and mouse responses to negative stimuli compared | Widens the technique from single cells to whole circuits and to cross-species questions |
"When you think about light in science or medicine, you think of it as an observational tool," Deisseroth told STAT after the announcement. "But with optogenetics, it's the complete opposite of that. We're not using light to collect information, we're using light to cause things to happen."
The Nobel Committee's chair, Per Svenningsson, put the result in one sentence: "Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of."
Why This Matters to Actual People
This is where a technique developed in mice stops being abstract. Optogenetics gave scientists something neuroscience had almost never had: proof of cause and effect inside a living brain. You can watch a behaviour, switch off one group of cells, and see what disappears. That is how you find out which circuit does what.
Several findings from Deisseroth's lab and its collaborators matter directly to people:
- Parkinson's disease. Working with Anatol Kreitzer at the University of California, San Francisco, Deisseroth identified two nerve-cell circuits that play a key role in the disorder, and the team was able to reverse Parkinson's symptoms in mice using light.
- Depression. His lab induced and then relieved depression-like symptoms in mice, work that helps explain which circuits carry mood states.
- Social behaviour and autism. He found a brain circuit that governs the drive to interact socially, then triggered or suppressed social interaction in mice. He has also applied optogenetics to autism research and used the CLARITY technique on donated postmortem human brain tissue from people with autism.
- Anxiety and the body. For a century psychologists debated whether emotion starts in the brain or the body. His team placed light-sensitive microbial proteins in the hearts of mice and looked for fear and anxiety responses. They found them. The full anxious state, in his words, required interaction between the brain and the body.
None of this is a cure. It is the map you need before you can build the cure.
Where human use stands: Optogenetics is not yet a routine human treatment. It is currently a research tool used in animals and in donated tissue. Stanford notes it can be adapted to other cell types, including heart and pancreas cells, and may eventually be used in people alongside gene therapy, for example to restore function in paraplegia. Researchers are also exploring its role in brain-computer interfaces for people with spinal cord injuries or strokes. Deisseroth has described those human applications as further out but genuinely promising.
The Early Years Nobody Remembers
There is a detail in the funding record that deserves a moment. Deisseroth started his lab at Stanford in 2004. In 2005, before the field existed, the National Institutes of Health gave him a Director's Pioneer Award, with the review comment that his proposal was "quite an unprecedented, highly innovative proposal, bordering on the unknown."
The same year, and again in 2007, he received a Young Investigator Award from the Brain & Behavior Research Foundation, when he was still building his laboratory. He joined that foundation's scientific council in 2008 and received its Goldman-Rakic Prize in 2013.
He has said publicly that when an investigator has unusual, risky ideas, funding can be hard to find. That sentence is worth keeping, because the technique that just won a Nobel Prize was once a research proposal that reviewers could easily have rejected.
He also gave the tool away. At Stanford, he built an optogenetics training programme that has taught thousands of scientists how to use the method, and his lab distributed copies of the engineered opsin gene to laboratories worldwide. That is why the technique spread with unusual speed. Erin O'Shea, president of the Howard Hughes Medical Institute, described him as generous with both training and support.
The Question Everyone Is Asking: What About Ed Boyden?
No honest account of this Nobel can skip this, because it was the loudest conversation on social media the day of the announcement.
Ed Boyden was the first author on Deisseroth's landmark 2005 optogenetics paper. He was a PhD student in the lab at the time and is now a professor at MIT. Feng Zhang, now at MIT as well, was second author. Nobel rules cap a prize at three recipients, and the committee chose Deisseroth, Hegemann and Nagel. Many scientists argued publicly that Boyden should have been included.
The committee did acknowledge others in its background material, naming Gero Miesenböck, who achieved the first genetic light-sensitisation of non-photoreceptive neurons in 2002, and Zhuo-Hua Pan, who in 2004 successfully tested channelrhodopsin in ganglion cells. Boyden did not respond to requests for comment.
Deisseroth himself pointed to the wider community. When he learned the prize was shared, he told reporters he was glad the trio spanned the whole journey, from algal biology to advanced neuroscience, and he named the students, staff and postdocs who work with him as part of the moment. Thomas Perlmann, secretary of the Nobel Committee, said all three laureates called the others "my friends."
This kind of dispute is familiar in science that moves fast. The Nobel rewards three people for work that hundreds built. That does not make the question unfair. It just means the prize is a highlight, not a complete history.
What He Says He Will Do Next
When reporters asked Deisseroth how he planned to celebrate, his answer was short and slightly funny: "Get back to work. We have a lot of things still to discover and a lot of people to help."
At a later press conference he added that he was looking forward to doing more science communication with the public, and specifically to sharing the story of how microbial proteins are helping researchers understand the human brain. His 10-year-old daughter Sophie reportedly had the best summary of the morning when she saw the news. "Dad," she said, "you've won all the prizes!"
He has not, technically, won all of them. There is still a transparent human brain to build, still the question of whether optogenetic tools can safely reach patients, and still the long grind of translating circuits into treatments for depression, Parkinson's and autism. What he does have is the thing that made the work possible in the first place: the habit of asking a question nobody had funded before, and then going back to the bench the next morning.
Frequently Asked Questions
Why is Karl Deisseroth trending right now?
Deisseroth was announced on October 5, 2026 as one of three winners of the Nobel Prize in Physiology or Medicine, sharing it with Peter Hegemann of Humboldt University in Berlin and Georg Nagel of the University of Würzburg. The Nobel Assembly honoured the three for discoveries concerning light-gated ion channels and optogenetics. He is trending because the award recognises a technique that changed how neuroscientists study the brain, and because his very ordinary reaction to the news resonated with people.
What is optogenetics in simple words?
Optogenetics is a technique that lets scientists switch individual brain cells on or off using light. A light-sensitive protein from algae, called channelrhodopsin, is delivered into chosen neurons. When blue light shines on those cells, the protein opens a channel and triggers a nerve signal within milliseconds. Researchers then insert a thin optical fiber into the brain of a living animal and control specific circuits, which lets them work out exactly which cells drive which behaviour.
Does optogenetics work in humans yet?
Not as a routine treatment. Optogenetics is currently a laboratory research tool used in animals and in donated tissue. Deisseroth and other researchers have said it could eventually reach humans alongside gene therapy, for example to restore function after spinal cord injury, and there is separate work exploring its use in brain-computer interfaces. Those applications remain experimental and years away from standard clinical care.
Why did Ed Boyden not receive the Nobel Prize?
Ed Boyden was the first author on Deisseroth's landmark 2005 optogenetics paper and was then a PhD student in his lab. Nobel rules allow a maximum of three living recipients per prize, and the committee selected Deisseroth, Hegemann and Nagel. The committee also named other contributors in its background material, including Gero Miesenböck and Zhuo-Hua Pan. Boyden has not publicly commented.
What kind of doctor is Karl Deisseroth?
He is a board-certified psychiatrist as well as a scientist. He completed his medical internship and adult psychiatry residency at Stanford and continues to see patients who live with treatment-resistant depression and autism spectrum disorder. He holds a PhD in neuroscience and an MD from Stanford, a position in bioengineering and psychiatry, and is a Howard Hughes Medical Institute investigator.
Sources and References
Government and official institutional sources are labelled clearly below.
- [Official award body, Sweden] The Nobel Assembly at Karolinska Institutet, Nobel Prize in Physiology or Medicine 2026 and the accompanying popular information page, nobelprize.org. Official citation, laureate biography and the scientific narrative of channelrhodopsin and optogenetics (October 5, 2026).
- [Government agency, USA] National Institutes of Health. The NIH Director's Pioneer Award granted to Deisseroth in 2005, with the reviewers' description of his proposal as "quite an unprecedented, highly innovative proposal, bordering on the unknown," as reported by STAT.
- [Official university source] Stanford Medicine news release, "Stanford University professor Karl Deisseroth wins 2026 Nobel Prize in physiology or medicine," med.stanford.edu (October 5, 2026). Family details, the sandwich list, laboratory history, research applications and quotes from colleagues Rob Malenka and Laura Roberts.
- [Official research institute] Howard Hughes Medical Institute, "Karl Deisseroth Awarded the 2026 Nobel Prize in Physiology or Medicine," hhmi.org (October 5, 2026). Technical explanation of channelrhodopsin delivery and quotes from HHMI president Erin O'Shea and chief scientific officer Leslie Vosshall.
- [News agency] Associated Press, distributed via AP News, US News and Newsday, "California scientist wins a Nobel Prize, then makes school lunches for his kids" (October 5, 2026). The 12:27 a.m. call, "no real sleep was achieved," the 6:30 a.m. break and the faculty housing exchange.
- [News media] STAT, "2026 Nobel Prize in Medicine awarded for brain research tool called optogenetics" (October 5, 2026). Direct quotes from Deisseroth on light, the Nobel Committee, and reporting on Ed Boyden, Gero Miesenböck and Zhuo-Hua Pan.
- [News media] Palo Alto Online, "Karl Deisseroth, Stanford's 'renaissance man,' celebrates Nobel Prize" (October 5, 2026). Dean Jennifer Widom's remarks, prize value, Stanford laureate count and Deisseroth's plans for public science communication.
- [Nonprofit research funder] Brain & Behavior Research Foundation, congratulatory release (October 5, 2026). Deisseroth's 2005 and 2007 Young Investigator Awards, 2008 Scientific Council membership and 2013 Goldman-Rakic Prize.
- [Research foundation] Simons Foundation, "Former SFARI Investigator Karl Deisseroth Wins 2026 Nobel Prize" (October 5, 2026). His autism research funding and the CLARITY technique applied to donated human brain tissue.
- [Scientific literature] Deisseroth and colleagues, Nature Neuroscience (2005) landmark optogenetics paper with Ed Boyden as first author; subsequent literature on inhibitory opsins, ensemble optogenetics and the study comparing human and mouse responses to adverse stimuli.
- [Book] Karl Deisseroth, Projections: A Story of Human Emotions (2021), published in the UK under the title Connections: The New Science of Emotion. Patient-centred accounts of mania, depression, eating disorders, autism and dementia.
Bottom Line
Karl Deisseroth won the 2026 Nobel Prize in Physiology or Medicine for turning a light-sensitive protein from a single-celled alga into a switch that can turn individual brain cells on and off inside a living animal. That tool, optogenetics, changed what neuroscience could prove, and it is already being used to untangle circuits involved in Parkinson's disease, depression, autism and social behaviour.
The genuinely human part is smaller than the science. A 54-year-old psychiatrist who still treats patients, works past midnight and reads poetry learned at 12:27 a.m. that he had won science's biggest prize, then asked for an hour off at 6:30 a.m. because his kids needed lunch. There are, as his wife pointed out, a lot of Nobels in that neighbourhood. There are not many who make six sandwiches first.
Safety Note: Optogenetics is an experimental research technique, not an available treatment for any condition, and it should not be sought out as a therapy. If you are affected by depression, autism spectrum disorder, Parkinson's disease or any psychiatric or neurological condition, please consult a qualified clinician or a licensed mental health professional rather than relying on research summaries or news reports.
Comments
Post a Comment